GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Theratechnologies Inc (NAS:THTX) » Definitions » Debt-to-Revenue

Theratechnologies (Theratechnologies) Debt-to-Revenue : 0.91 (As of Feb. 2024)


View and export this data going back to 2011. Start your Free Trial

What is Theratechnologies Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Theratechnologies's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Feb. 2024 was $12.79 Mil. Theratechnologies's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Feb. 2024 was $46.36 Mil. Theratechnologies's annualized Revenue for the quarter that ended in Feb. 2024 was $64.99 Mil. Theratechnologies's annualized Debt-to-Revenue for the quarter that ended in Feb. 2024 was 0.91.


Theratechnologies Debt-to-Revenue Historical Data

The historical data trend for Theratechnologies's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Theratechnologies Debt-to-Revenue Chart

Theratechnologies Annual Data
Trend Nov14 Nov15 Nov16 Nov17 Nov18 Nov19 Nov20 Nov21 Nov22 Nov23
Debt-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.80 0.84 0.81 0.83 0.72

Theratechnologies Quarterly Data
May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.83 0.95 0.70 0.63 0.91

Competitive Comparison of Theratechnologies's Debt-to-Revenue

For the Biotechnology subindustry, Theratechnologies's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Theratechnologies's Debt-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Theratechnologies's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Theratechnologies's Debt-to-Revenue falls into.



Theratechnologies Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Theratechnologies's Debt-to-Revenue for the fiscal year that ended in Nov. 2023 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(7.707 + 51.261) / 81.764
=0.72

Theratechnologies's annualized Debt-to-Revenue for the quarter that ended in Feb. 2024 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(12.785 + 46.355) / 64.988
=0.91

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Feb. 2024) Revenue data.


Theratechnologies Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Theratechnologies's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Theratechnologies (Theratechnologies) Business Description

Traded in Other Exchanges
Address
2015, rue Peel, 11e etage, Montreal, QC, CAN, H3A 1T8
Theratechnologies Inc is a specialty pharmaceutical company that addresses the unmet medical needs of HIV patients. It mainly operates in Canada and the United States. The company has two approved products, EGRIFTA marketed in Canada and the United States, and Trogarzo approved for commercialization in the United States.